Eidos Therapeutics Inc (EIDX) Stock Price & Overview
NASDAQ:EIDX
Current stock price
The current stock price of EIDX is 122.21 null. Today EIDX is down by -4.85%. In the past month the price decreased by -4.04%. In the past year, price increased by 129.37%.
EIDX Key Statistics
- Market Cap
- 4.751B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.65
- Dividend Yield
- N/A
EIDX Stock Performance
EIDX Stock Chart
EIDX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to EIDX. When comparing the yearly performance of all stocks, EIDX is one of the better performing stocks in the market, outperforming 91.31% of all stocks.
EIDX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EIDX. While EIDX has a great health rating, there are worries on its profitability.
EIDX Earnings
EIDX Forecast & Estimates
EIDX Financial Highlights
Over the last trailing twelve months EIDX reported a non-GAAP Earnings per Share(EPS) of -2.6500000000000004. The EPS decreased by -231.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -79392.91% | ||
| ROA | -62.49% | ||
| ROE | N/A | ||
| Debt/Equity | 0.14 |
EIDX Ownership
About EIDX
Company Profile
Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States.
Company Info
Eidos Therapeutics Inc
101 MONTGOMERY STREET SUITE 2550
SAN FRANCISCO CA 94104
CEO: Neil Kumar
Phone: 415-887-1471
Eidos Therapeutics Inc / EIDX FAQ
What does Eidos Therapeutics Inc do?
Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States.
What is the stock price of Eidos Therapeutics Inc today?
The current stock price of EIDX is 122.21 null. The price decreased by -4.85% in the last trading session.
What is the dividend status of Eidos Therapeutics Inc?
EIDX does not pay a dividend.
What is the ChartMill rating of Eidos Therapeutics Inc stock?
EIDX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of EIDX stock?
Eidos Therapeutics Inc (EIDX) has a market capitalization of 4.75B null. This makes EIDX a Mid Cap stock.
Who owns Eidos Therapeutics Inc?
You can find the ownership structure of Eidos Therapeutics Inc (EIDX) on the Ownership tab.